Document:

LICENSE AGREEMENT DATED JUNE 9, 2002

 Exhibit 10.19 
  
 [********] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  
 LICENSE AGREEMENT 
  
 between 
  
 MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE,
INC. 
  
 and 
  
 TARGACEPT, INC. 
  

 7/3/02 
  
 TABLE OF CONTENTS 
  

			
	Article 1.	  	Definitions
		
	Article 2.	  	Grant of License
		
	Article 3.	  	Diligence and Commercialization
		
	Article 4.	  	Consideration for License
		
	Article 5.	  	Reports and Payments
		
	Article 6.	  	Records
		
	Article 7.	  	Patent Prosecution
		
	Article 8.	  	Abatement of Infringement
		
	Article 9.	  	Confidentiality
		
	Article 10.	  	Merchantability and Exclusion of Warranties
		
	Article 11.	  	Damages, Indemnification, and Insurance
		
	Article 12.	  	Term and Termination
		
	Article 13.	  	Assignment
		
	Article 14.	  	Miscellaneous
		
	Article 15.	  	Notices
		
	Exhibit A.	  	Licensed Patents
		
	Exhibit B.	  	Licensee’s Development Plan
		
	Exhibit C.	  	Equity Distributions

  

 THIS LICENSE AGREEMENT is made and entered into as of this 9th day of June, 2002, by and between the
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC., a nonprofit Georgia corporation with offices located in the Medical College of Georgia, 1120 15th Street, Room CJ-3301, Augusta, Georgia 30912-4810 (hereinafter referred to as “MCGRI”)
and TARGACEPT, INC., a corporation with corporate headquarters located at 200 East First Street, Suite 300, Winston-Salem, NC 27101-4165 (hereinafter referred to as LICENSEE”). 
  
 WITNESSETH 
  
 WHEREAS, the Medical College of Georgia Research Institute (MCGRI) is the assignee of all right, title, and interest in inventions developed by employees
of The Medical College of Georgia (MCG) and is responsible for the protection and commercial development of such inventions; and 
  
 WHEREAS, Dr. Mario Marrero, during the course of his employment by the Medical College of Georgia (MCG), developed certain inventions (MCG Case # 016-02
“Methods and Compositions for Treatment of Central Nervous System Disorders”) as more fully defined herein; and jointly owned by Targacept through its co-inventor, Dr. Merouane Bencherif; 
  
 WHEREAS, MCGRI wants to have the inventions further developed and made
available in commerce for use by the public; and 
  
 WHEREAS,
LICENSEE represents that it has the necessary expertise and resources to fully develop and commercialize the inventions; and 
  
 WHEREAS, LICENSEE wishes to obtain certain rights to pursue the development and commercialization of the inventions; and 
  
 WHEREAS, MCGRI wishes to grant LICENSEE such rights in accordance with the
terms and conditions of this Agreement. 
  
 NOW, THEREFORE, for
and in consideration of the mutual covenants and the premises herein contained, the parties, intending to be legally bound, hereby agree as follows. 
  
 ARTICLE 1. DEFINITIONS 
  
 The following terms as used herein shall have the following meaning: 
  
 1.1 “Agreement” or “License Agreement” shall mean this Agreement, including all Exhibits attached to
this Agreement. 
  
 1.2 “Field of Use” means Any and
All. 
  
 1.3 “Indemnitees” shall mean MCGRI,
MCGRI’s officers and directors, MCG, MCG’s employees, and the Inventors, and their heirs, executors, administrators, and legal representatives. 
  

 1.4 “Inventors” shall mean Drs. Mario Marrero and Dr. Merouane Bencherif, each of which will
share in intellectual property income according to the policies of their employing institution. 
  
 1.5 “License Agreement Year” shall mean the period from July 1 through June 30 of each year during the term of this Agreement. 
  
 1.6 “Licensed Patents” shall mean the inventions embodied in the
patent applications and patents identified in EXHIBIT A hereof, together with all divisionals, continuations, reissues, and foreign counterparts of such applications or patents. 
  
 1.7 “Licensed Product(s)” shall mean any process, service, or product, the manufacture, use, or sale of which is
covered by a Valid Claim or incorporates or uses any Licensed Technology. 
  
 1.8 “Licensed Technology” shall mean all information and materials proprietary to MCGRI, including designs, technical information, know how, knowledge, data, specifications, test results and other
information relating to the Licensed Patents and disclosed by MCGRI to LICENSEE on the date of this Agreement or during the term hereof. 
  
 1.9 “Licensed Territory” means the World. 
  
 1.10 “LICENSEE’s Development Plan” shall mean EXHIBIT B of this Agreement. 
  
 1.11 “Net Selling Price” of Licensed Products shall mean [********]. 
  
 1.12 “Sale” or “Sold” shall mean the sale, transfer,
exchange, or other disposition of Licensed Products whether by gift or otherwise, including but not limited to the use of Licensed Products by LICENSEE or any other person authorized by LICENSEE. Sales of Licensed Products shall be deemed
consummated upon the first to occur of: (a) receipt of payment from the purchaser; (b) delivery of Licensed Products to the purchaser or a common carrier; (c) release of Licensed Products from consignment; (d) if deemed Sold by use, when first put
to such use; or (e) if otherwise transferred, exchanged, or disposed of whether by gift or otherwise when such transfer, exchange, gift, or other disposition occurs. 
  
 1.13 “MCG” shall mean The University of Georgia. 
  
 1.14 “Valid Claim” shall mean a claim included among the Licensed Patents so long as such claim shall not have
been irrevocably abandoned or held invalid in an unappealable decision of a court or other authority of competent jurisdiction. 
  
 ARTICLE 2. GRANT OF LICENSE 
  
 2.1 License. MCGRI hereby grants LICENSEE an exclusive right and license to MCGRI’s rights to make, use, and Sell Licensed Products for the
Field of Use in the Licensed Territory during the term of this Agreement. 
  

 2.2 Retained License. MCGRI retains on behalf of itself, MCG, and any research collaborators, a
royalty-free right and license to make and use Licensed Products and to practice Licensed Technology for research and educational purposes only. 
  
 2.3 No Implied License. The license and right granted in this Agreement shall not be construed to confer any rights upon LICENSEE by implication,
estoppel, or otherwise as to any technology not specifically identified in this Agreement as Licensed Patents or Licensed Technology. 
  
 2.4 Government Rights. The Licensed Patents, Licensed Technology, or portions thereof may have been developed with financial or other assistance
through grants or contracts funded by the United States government. LICENSEE acknowledges that in accordance with Public Law 96-517 and other statutes, regulations, and Executive Orders as now exist or may be amended or enacted, the United States
government has certain rights in the Licensed Patents and Licensed Technology. LICENSEE shall take all action necessary to enable MCGRI to satisfy its obligations under any federal law relating to the Licensed Patents or Licensed Technology. If the
United States government should take action which renders it impossible or impractical for MCGRI to grant the rights and license granted herein to LICENSEE under this Agreement or otherwise perform MCGRI’s obligations under this Agreement,
MCGRI or LICENSEE may terminate this Agreement immediately by notice to the other party. LICENSEE shall not have any right to the return of any payments of any kind made by it to MCGRI prior to the date of termination. 
  
 ARTICLE 3. DILIGENCE AND COMMERCIALIZATION 
  
 3.1 LICENSEE shall use its best efforts throughout the term of this Agreement
to comply with LICENSEE’s Development Plan and to bring Licensed Products to market through a thorough, vigorous, and diligent program for exploitation of the right and license granted in this Agreement to LICENSEE and to create, supply, and
service in the Licensed Territory as extensive a market as practical. In no instance shall LICENSEE’s best efforts be less than efforts customary in LICENSEE’s industry. 
  
 ARTICLE 4. CONSIDERATION FOR LICENSE 
  
 4.1 License Fee. As partial consideration for the license granted to LICENSEE under this Agreement, LICENSEE shall
pay MCGRI a license fee of [********] at signing, or within ten (10) days of signing, this Agreement. 
  
 4.2 Sublicensing Fee. Licensee shall pay MCGRI [********] of any fees or payments or non-royalty remuneration, not including Milestone
Payments (4.4) paid to LICENSEE by a sublicensee in relation to this License and for rights to all or part of the Licensed Patents 
  
 4.3 Royalties. As partial consideration for the license granted to LICENSEE under this Agreement, MCGRI shall earn a royalty equal to
[********] of the Net Selling Price of all Licensed Products 

  

 
Sold by LICENSEE or Sublicensee during the term of this Agreement. There shall be an annual minimum royalty of [********] effective the first year of
product sales. 
  
 4.4 Milestone Payments: 
  

	 	•	[********] 

  

	 	•	[********] 

  

	 	•	[********] 

  

	 	•	[********] 

  
 The above payments are due to MCGRI regardless of whether clinical trials and regulatory activities are conducted by LICENSEE or Sublicensee. 

 
 4.5 Reimbursement for Patent Expenses. LICENSEE shall assume the
responsibility and cost of out-of-pocket fees, costs, and expenses hereafter during the term of this Agreement incurred in filing, prosecuting, and maintaining the Licensed Patents in the Licensed Territory. 
  
 ARTICLE 5. REPORTS AND PAYMENTS 
  
 5.1 Within thirty (30) days of September 30, December 31, March 31, and June
30 of each year during the term of this Agreement, up to and including September 30, December 31, March 31 and June 30 following the termination or expiration of this Agreement, LICENSEE shall render a written report to MCGRI setting forth for the
preceding calendar quarter, the following as may be applicable under the royalty provisions hereof: 
  
 (a) the Net Sales Value of all Licensed Products Sold by LICENSEE, Affiliates, and sublicensees under this Agreement; and 
  
 (b) the amount of royalty payable; and 
  
 (c) any other information reasonably necessary to show the
basis on which such royalty has been computed; and 
  
 (d) the title of the Licensed Patent(s), the inventor(s), and the five digit MCG code(s) for the Licensed Patent(s). 
  
 (e) in case no payment is due for any calendar quarter hereunder, LICENSEE shall so report. 
  
 (f) the amount spend on patent prosecution for the licensed
intellectual property. 
  
 5.2 Each royalty report shall be
accompanied by the payment of all royalties due for the quarter calendar year in question. 
  
 5.3 All royalties shall be paid in United States funds collectible at one hundred percent (100%) of face value in New York, New York, U.S.A. For purposes of computing the royalty payment on Sales outside the United
States, the royalty payment hereunder shall first be determined in the foreign currency of the 

  

 
country in which Licensed Products are Sold and then converted to United States dollars at the spot rate published by the Wall Street Journal (U.S.
edition) on the last day of the quarter for which payment is due. 
  
 5.4 In high inflation countries where LICENSEE uses accounting treatment under Statement of Financial Accounting Standards No. 52, Paragraph 11, or the successor equivalent Standard, LICENSEE may for each such country at the end of each
quarter convert each month’s Sales in that quarter to United States dollars by assuming all Sales in that month occurred on the last day of the month, computing the collection date for that month’s Sales to United States dollars at the
forecasted exchange rate for that computed collection date; differences between the forecasted exchange rate and the actual exchange rate are to be corrected in the first quarter in which known. 
  
 5.5 If Licensed Products are Sold in a country in which conditions or legal
restrictions exist which prohibit remittance of United States dollars, LICENSEE shall have the right and option to make the royalty payment for such country by depositing the amount thereof in the currency of the country of Sale at LICENSEE’s
election, to MCGRI ‘s account in a bank designated by MCGRI in such country. 
  
 5.6 Interest. Payments required under this Agreement shall, if overdue, bear interest until payment at a per annum rate [********] above the prime rate in effect at the Trust Company Bank in Atlanta,
Georgia, on the due date. The payment of such interest shall not foreclose MCGRI from exercising any other rights it may have because any payment is late. 
  
 5.7 All payments and reports due under this Agreement shall be made in person or via the United States mail or private carrier to the following address:

  
 Medical College of Georgia Research Institute, Inc.

 Attn: Director, Office of Biomedical Technology Transfer 
 CJ-3301 
 Medical College of Georgia 
 Augusta, Georgia 30912-4810 
 Facsimile: (706)
721-9517 
  
 5.8 All payments should be made payable to: The
Medical College of Georgia Research Institute, and must refer to the technology transfer case # (016-02). 
  
 ARTICLE 6. RECORDS 
  
 6.1 Records of Sales. During the term of this Agreement and for a period of three (3) years thereafter, LICENSEE shall keep at its principal place of business true and accurate records of all Sales in
accordance with general accepted accounting principles in the respective country where such Sales occur and 

  

 
in such form and manner so that all royalties owed to MCGRI may be readily and accurately determined. LICENSEE shall furnish MCGRI copies of such records
upon MCGRI’s request, which shall not be made more often than once per License Agreement Year. 
  
 6.2 Audit of Records. MCGRI shall have the right, from time to time at reasonable times during normal business hours through an independent
certified public accountant, to examine the records of LICENSEE in order to verify the calculation of any royalties payable under this Agreement. Such examination and verification shall not occur more than once each License Agreement Year and the
calendar year immediately following termination of this Agreement. Unless otherwise agreed in writing by LICENSEE, the fees and expenses of performing such examination and verification shall be borne by MCGRI. If such examination reveals an
underpayment by LICENSEE of more than [********] for any quarter examined, LICENSEE shall pay MCGRI the amount of such underpayment plus interest and shall reimburse MCGRI for all expenses of the accountant performing the examination.

  
 ARTICLE 7. PATENT PROSECUTION 
  
 7.1 Prosecution and Maintenance of Licensed Patents. The prosecution
and maintenance of the Licensed Patents shall be the primary responsibility of LICENSEE. LICENSEE shall keep MCGRI informed as to all developments with respect to Licensed Patents. MCGRI shall be afforded reasonable opportunities to advise LICENSEE
and cooperate with LICENSEE in such prosecution and maintenance. 
  
 LICENSEE, upon ninety (90) days advance written notice to MCGRI, may advise MCGRI that it no longer wishes to pay expenses for filing, prosecuting or maintaining one or more Licensed Patents. MCGRI may, at its option, elect to pay such
expenses or permit such Licensed Patents to become abandoned or lapsed. If MCGRI elects to pay such expenses, such patents shall not be subject to any license granted to LICENSEE hereunder. 
  
 ARTICLE 8. ABATEMENT OF INFRINGEMENT 
  
 8.1 LICENSEE shall promptly inform MCGRI of any suspected infringement of any
Licensed Patents. During the term of this Agreement, MCGRI and LICENSEE shall have the right to institute an action for infringement of the Licensed Patents against any such third party in accordance with the following and subject to the rights of
any third parties granted licenses to practice the Licensed Patents by MCGRI: 
  
 (a) If MCGRI and LICENSEE agree to institute suit jointly, the suit shall be brought in both their names, the out-of-pocket costs thereof shall be borne equally, and any recovery or settlement shall be shared equally.
LICENSEE and MCGRI shall agree upon the manner in which they shall exercise control over such action. MCGRI may, if it so desires, also be represented by separate counsel of its own selection. The fees for which counsel shall be paid by MCGRI;

  

 (b) In the absence of agreement to institute a suit jointly, MCGRI may institute suit,
and, at its option, name LICENSEE as a plaintiff. MCGRI shall bear the entire cost of such litigation and shall be entitled to retain the entire amount of any recovery or settlement; and 
  
 (c) In the absence of agreement to institute a suit jointly and if MCGRI notifies LICENSEE that it has
decided not to join in or institute a suit, as provided in (a) or (b) above, LICENSEE may institute suit and, at its option, name MCGRI as a plaintiff. LICENSEE shall bear the entire cost of such litigation, including defending any counterclaims
brought against MCGRI and paying any judgments rendered against MCGRI, and shall be entitled to retain the entire amount of any recovery or settlement. 
  
 8.2 Should either MCGRI or LICENSEE commence a suit under the provisions of this Article and thereafter elect to abandon such suit, the abandoning party
shall give timely notice to the other party who may, if it so desires, continue prosecution of such suit, provided that the sharing of expenses and any recovery in such suit shall be as agreed upon between MCGRI and LICENSEE. 
  
 ARTICLE 9. CONFIDENTIALITY 
  
 9.1 LICENSEE shall not, without the express written consent of MCGRI, for any
reason or at any time either during or subsequent to the term of this Agreement disclose any information contained in the Licensed Patents or Licensed Technology or any other information pertaining to the Licensed Patents and Licensed Technology
(collectively referred to as “Proprietary Information”) to third parties other than Affiliates and LICENSEE’s sublicensees. This obligation of nondisclosure shall not extend to information: 
  
 (a) which LICENSEE can demonstrate through documentation to
have been within LICENSEE’s legitimate possession prior to the time of disclosure of such information to LICENSEE by MCGRI, MCG, or the Inventors; 
  
 (b) which was in the public domain prior to disclosure by MCGRI, MCG, or the Inventors, as evidenced by documents published prior to such
disclosure; 
  
 (c) which, after disclosure by
MCGRI, MCG, or the Inventors, comes into the public domain through no fault of LICENSEE; 
  
 (d) which is disclosed to LICENSEE by a third party having legitimate possession of the information and the unrestricted right to make
such disclosure. 
  
 9.2 Prior Agreements. The provisions
of this Agreement supersede and shall be substituted for any terms of any prior confidentiality agreement between LICENSEE and MCGRI which are not consistent with this Agreement. 
  

 ARTICLE 10. MERCHANTABILITY AND EXCLUSION OF WARRANTIES 
  
 10.1 LICENSEE possesses the necessary expertise and skill in the technical
areas in which the Licensed Products and Licensed Technology are involved to make, and has made, its own evaluation of the capabilities, safety, utility, and commercial application of the Licensed Patents and Licensed Technology. ACCORDINGLY, MCGRI
MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE LICENSED PATENTS OR LICENSED TECHNOLOGY AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED WARRANTIES WITH RESPECT
TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL APPLICATION OF LICENSED PATENTS OR LICENSED TECHNOLOGY. 
  
 ARTICLE 11. DAMAGES, INDEMNIFICATION, AND INSURANCE 
  
 11.1 NO LIABILITY. MCGRI shall not be liable to LICENSEE or LICENSEE’s customers for special, incidental, indirect, or consequential damages
resulting from defects in the design, testing, labeling, manufacture, or other application of Licensed Products manufactured, tested, designed, or Sold pursuant to this Agreement. 
  
 11.2 Indemnification. LICENSEE shall defend, indemnify, and hold harmless the Indemnitees from and against any and
all claims, demands, loss, liability, expense, or damage (including investigative costs, court costs and attorneys’ fees) Indemnitees may suffer, pay, or incur as a result of claims, demands or actions against any of the Indemnitees arising or
alleged to arise by reason of or in connection with any and all personal injury and property damage caused or contributed to in whole or in part by LICENSEE’s manufacture, testing, design, use, sale, or labeling of any Licensed Products, or the
practice of any Licensed Patents. LICENSEE’s obligations under this Article shall survive the expiration or termination of this Agreement for any reason. 
  

11.3 Insurance. Without limiting LICENSEE’s indemnity obligations under the preceding paragraph, LICENSEE shall maintain throughout the
term of this Agreement and for ten (10) years thereafter a liability insurance policy which: 
  
 (a) insures Indemnitees for all claims, damages, and actions mentioned in Article 10.1 of this Agreement; 
  
 (b) includes a contractual endorsement providing coverage
for all liability which may be incurred by Indemnitees in connection with this Agreement; 
  
 (c) requires the insurance carrier to provide MCGRI with no less than thirty (30) days written notice of any change in the terms or
coverage of the policy or its cancellation; and 
  

 (d) provides Indemnitees product liability coverage in an amount no less than One Million
Dollars ($1,000,000) per occurrence for bodily injury and Five Million Dollars ($5,000,000) per occurrence for property damage, subject to a reasonable aggregate amount. 
  
 11.4 Notice of Claims. LICENSEE shall promptly notify MCGRI of all claims involving the Indemnitees and will advise
MCGRI of the policy amounts that might be needed to defend and pay any such claims. 
  
 ARTICLE 12. TERM AND TERMINATION 
  
 12.1 Term. Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement shall commence on the date hereof and shall continue until the earlier of [********] from the date hereof or the date of
expiration of the last to expire of the Licensed Patents, including any renewals or extensions thereof. 
  
 12.2 Termination. MCGRI shall have the right to terminate this Agreement upon the occurrence of any one or more of the following events:

  
 (a) failure of LICENSEE to make any two
payments consecutive required pursuant to this Agreement when due; or 
  
 (b) failure of LICENSEE to render reports to MCGRI as required by this Agreement; or 
  
 (c) failure of LICENSEE to notify MCGRI of intent to file bankruptcy as set forth in Article 12.3 below; 
  
 (d) the insolvency of LICENSEE; or 
  
 (e) the institution of any proceeding by LICENSEE under any
bankruptcy, insolvency, or moratorium law; or 
  
 (f) any assignment by LICENSEE of substantially all of its assets for the benefit of creditors; or 
  
 (g) placement of LICENSEE’s assets in the hands of a trustee or a receiver unless the receivership or trust is dissolved within
thirty (30) days thereafter; or 
  
 (h) the
failure of LICENSEE to comply with LICENSEE’s Development Plan; or 
  
 (i) the breach of any other material term of this Agreement. 
  
 12.3 Notice of Bankruptcy. The LICENSEE must inform MCGRI of its intention to file a voluntary petition in bankruptcy or of another’s intention to file an involuntary petition in bankruptcy to be received
at least thirty (30) days prior to filing such a petition. A party’s filing without conforming to this requirement shall be deemed a material, pre-petition incurable breach. 
  
 12.4 Exercise. MCGRI may exercise its right of termination by giving LICENSEE, its trustees or receivers or assigns,
thirty (30) days prior written notice of MCGRI’s election to terminate. Upon the expiration of such period, this Agreement shall automatically terminate unless the LICENSEE has cured the 

  

 
breach. Such notice and termination shall not prejudice MCGRI’s right to receive royalties or other sums due hereunder and shall not prejudice any cause
of action of claim of MCGRI accrued or to accrue on account of any breach or default by LICENSEE. 
  
 12.5 Failure to Enforce. The failure of MCGRI at any time, or for any period of time, to enforce any of the provisions of this Agreement shall not
be construed as a waiver of such provisions or as a waiver of the right of MCGRI thereafter to enforce each and every such provision. 
  
 12.6 Termination by LICENSEE. LICENSEE shall have the right to terminate this Agreement upon the occurrence of either of the following events:

  
 (a) the breach of a material term of this
Agreement by MCGRI; or 
  
 (b) If the Sale of
Licensed Products requires approval by any government agency, and after diligent pursuit of such approval, including but not limited to; performing all alternative tests or analyses as prescribed by such agency regulations, submitting all relevant
data to such agency, and pursuing all available administrative procedures and appeal processes permitted by such agency and applicable law, LICENSEE is unable to obtain approval for the Sale of Licensed Products, LICENSEE may notify MCGRI in writing
of the final denial of approval to Sell Licensed Products and LICENSEE’s desire to terminate this Agreement. MCGRI shall either grant LICENSEE’s request for termination of such Agreement or, at MCGRI’s sole option, request LICENSEE to
provide MCGRI with all files and records pertaining to such applications and permit MCGRI access to all documents and records in the possession of any regulatory authority pertaining to any application by LICENSEE so as to enable MCGRI to verify
LICENSEE’s efforts to obtain approval for the Sale of Licensed Products. MCGRI shall further be entitled to retain consultants on a confidential basis to assist MCGRI in completing its review. If MCGRI, in its sole discretion, determines that
LICENSEE has diligently pursued approval for the Sale of Licensed Products and failed to obtain such approval, MCGRI shall grant LICENSEE’s request to terminate the Agreement. 
  
 12.7 Exercise. LICENSEE may exercise its right of termination based upon a material breach of this Agreement by MCGRI
by giving MCGRI thirty (30) days prior written notice of LICENSEE’s election to terminate. Upon the expiration of such period, this Agreement shall automatically terminate unless MCGRI has cured the breach. Such notice and termination shall not
prejudice LICENSEE’s right to pursue any other remedies available to LICENSEE at law. 
  
 Licensee may exercise its right of termination as a result of the failure to obtain approval to Sell Licensed Products by providing MCGRI with a formal written request for such termination. MCGRI shall provide
LICENSEE with a formal written response to LICENSEE’s request for termination within forty-five (45) days of receiving such request. 
  
 12.8 Effect. In the event this Agreement is terminated for any reason whatsoever, LICENSEE shall return, or at MCGRI’s direction destroy, all
plans, drawings, papers, notes, writings and other documents, 

  

 
samples, organisms, biological materials and models pertaining to the Licensed Patents and Licensed Technology, retaining no copies, and shall refrain from
using or publishing any portion of the Licensed Patents or Licensed Technology as provided in Article 8 of this Agreement. Upon termination of this Agreement, LICENSEE shall cease manufacturing, processing, producing, using, Selling, or distributing
Licensed Products; provided, however, that LICENSEE may continue to Sell in the ordinary course of business for a period of one (1) year reasonable quantities of Licensed Products which are fully manufactured and in LICENSEE’s normal inventory
at the date of termination if (a) all monetary obligations of LICENSEE to MCGRI have been satisfied and (b) royalties on such sales are paid to MCGRI in the amounts and in the manner provided in this Agreement. The provisions of Articles 9, 10, and
11 of this Agreement shall remain in full force and effect notwithstanding the termination of this Agreement. 
  
 ARTICLE 13. ASSIGNMENT 
  
 13.1 This Agreement is dependent upon the special relationship between the parties and the special knowledge and unique skills of the LICENSEE. Therefore, LICENSEE shall not grant, transfer, convey, or otherwise assign any of its rights or
delegate any of its obligations under this Agreement without the prior written consent of MCGRI, except as explicitly permitted under this Agreement. This Agreement shall be assignable by MCGRI to MCG, or any other nonprofit corporation, which
promotes the education or research purposes of MCG. The above notwithstanding, LICENSEE is allowed to Sublicense to a third party provided they agree to the provisions of this Agreement. 
  
 ARTICLE 14. MISCELLANEOUS 
  
 14.1 Export Controls. LICENSEE acknowledges that MCGRI is subject to United States laws and regulations controlling the export of technical data,
computer software, laboratory prototypes, and other commodities and that MCGRI’s obligations under this Agreement are contingent upon compliance with applicable United States export laws and regulations. The transfer of technical data and
commodities may require a license from the cognizant agency of the United States government or written assurances by LICENSEE that LICENSEE shall not export data or commodities to certain foreign countries without the prior approval of certain
United States agencies. MCGRI neither represents that an export license shall not be required nor that, if required, such export license shall issue. 
  
 14.2 Legal Compliance. LICENSEE shall comply with all laws and regulations relating to its manufacture, processing, producing, use, Selling, or
distributing of Licensed Products. LICENSEE shall not take any action which would cause MCGRI or LICENSEE to violate any laws and regulations. 
  
 14.3 Independent Contractor. LICENSEE’s relationship to MCGRI shall be that of a licensee only. LICENSEE shall not be the agent of MCGRI and
shall have no authority to act for or on behalf of MCGRI in 

  

 
any matter. Persons retained by LICENSEE as employees or agents shall not by reason thereof be deemed to be employees or agents of MCGRI. 
  
 14.4 Patent Marking. LICENSEE shall mark Licensed Products Sold in the
United States with United States patent numbers. Licensed Products manufactured or Sold in other countries shall be marked in compliance with the intellectual property laws in force in such foreign countries. 
  
 14.5 Use of Names. LICENSEE shall obtain the prior written approval of
MCGRI, MCG, or the Inventors prior to making use of their names for any commercial purpose. 
  
 14.6 Place of Execution. This Agreement and any subsequent modifications or amendments hereto shall be deemed to have been executed in the State of Georgia, U.S.A. This Agreement shall not become effective or
binding upon MCGRI until signed on its behalf by its Executive Director in the State of Georgia, U.S.A. 
  
 14.7 Governing Law. This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder,
shall be construed under and governed by the laws of the State of Georgia and the United States of America. Only courts in the State of Georgia, U.S.A., shall have jurisdiction to hear and decide any controversy or claim between the parties arising
under or relating to this Agreement. 
  
 14.8 Entire
Agreement. This Agreement constitutes the entire agreement between MCGRI and LICENSEE with respect to the subject matter hereof and shall not be modified, amended or terminated except as herein provided or except by another agreement in writing
executed by the parties hereto. 
  
 14.9 Severability. All
rights and restrictions contained herein may be exercised and shall be applicable and binding only to the extent that they do not violate any applicable laws and are intended to be limited to the extent necessary so that they will not render this
Agreement illegal, invalid or unenforceable. If any provision or portion of any provision of this Agreement not essential to the commercial purpose of this Agreement shall be held to be illegal, invalid or unenforceable by a court of competent
jurisdiction, it is the intention of the parties that the remaining provisions or portions thereof shall constitute their agreement with respect to the subject matter hereof, and all such remaining provisions or portions thereof shall remain in full
force and effect. To the extent legally permissible, any illegal, invalid or unenforceable provision of this Agreement shall be replaced by a valid provision which will implement the commercial purpose of the illegal, invalid or unenforceable
provision. In the event that any provision essential to the commercial purpose of this Agreement is held to be illegal, invalid or unenforceable and cannot be replaced by a valid provision which will implement the commercial purpose of this
Agreement, this Agreement and the rights granted herein shall terminate. 
  
 14.10 Force Majeure. Any delays in, or failure of, performance of any party to this Agreement shall not constitute default hereunder, or give rise to any claim for damages, if and to the extent caused by

  

 
occurrences beyond the control of the party affected, including, but not limited to, acts of God, strikes or other work stoppages; civil disturbances, fires,
floods, explosions, riots, war, rebellion, sabotage, acts of governmental authority or failure of governmental authority to issue licenses or approvals which may be required. 
  
 ARTICLE 15. NOTICES 
  
 All notices, statements, and reports required or contemplated herein by one party to the other shall be in writing and shall be deemed to have been given
upon delivery in person or upon the expiration of five (5) days after deposit in a lawful mail depository in the country of residence of the party giving the notice, registered or certified airmail postage prepaid, and addressed as follows:

  

			
	If to MCGRI:	  	 
	 	  	 Director,
  
 Office of Biomedical Technology Transfer
  
 Medical College of Georgia Research Institute, Inc.
  
 CJ-2211
  
 Medical College of Georgia
  
 Augusta, Georgia 30912-4810
  
 Facsimile: (706) 721-9517

	If to LICENSEE:	  	 
	 	 	

	 	  	 
	 	 	

	 	  	 
	 	 	

	 	  	 
	 	 	

	 	  	 Facsimile:

  
 Either party hereto may change the
address to which notices to such party are to be sent by giving notice to the other party at the address and in the manner provided above. Any notice herein required or permitted to be given may be given, in addition to the manner set forth above,
by telex, facsimile or cable, provided that the party giving such notice obtains acknowledgement by telex, facsimile or cable that such notice has been received by the party to be notified. Notice made in this manner shall be deemed to have been
given when such acknowledgement has been transmitted. 
  

 IN WITNESS WHEREOF, MCGRI and LICENSEE have caused this Agreement to be signed by their duly authorized
representatives as of the day and year indicated below. 
  

			
	 MEDICAL COLLEGE OF GEORGIA
 RESEARCH INSTITUTE, INC.

		
	By:	 	 /s/ Betty Aldridge 

	 	 	

	 Name:
 Title:
	 	 Betty Aldridge
 Executive Director, MCGRI

  

			
	 LICENSEE:

		
	By:	 	 /s/ J. Donald deBethizy 

	 	 	

	 Name:
 Title:
	 	 J. Donald deBethizy
 President & CEO

  

 EXHIBIT A 
  
 Licensed Patents 
  
 The Medical College of Georgia and its Research Institute (“MCGRI”) hold certain title and rights in a joint invention on the alpha 7 nicotinic receptor
agonists and the JAK pathway with Targacept, Inc., specifically: 
  

			
	 Case #016-02:
	 	“Methods and Compositions for Treatment of Central Nervous System Disorders”
		
	 Inventors:
	 	 Drs. Mario Marrero and Merouane Bencherif

		
	 Patent Status:
	 	Provisional U.S. patent application prepared by Targacept, complete with data and claims.LICENSE AGREEMENT DATED MAY 26, 1999

 Exhibit 10.20 
  
 [********] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  
 LICENSE AGREEMENT 
  
 THIS AGREEMENT, made and entered into this 26th day of May, 1999, (the Effective Date) by and between the
University of Kentucky Research Foundation, a corporation duly organized and existing under the laws of the Commonwealth of Kentucky and having its principle office at Lexington, Kentucky, U.S.A. (hereinafter referred to as UKRF), and Targacept,
Inc., (“TARGACEPT”) a subsidiary of R.J.R. Reynolds Tobacco Company (“RJR”). 
  
 WITNESSETH 
  
 WHEREAS, TARGACEPT desires to obtain a license under the Patent Rights upon the terms and conditions hereinafter set forth, and 
  
 WHEREAS, UKRF previously has entered into agreements with RJR (and subsequently, TARGACEPT) regarding research and development activities concerning
nicotinic compounds for use in therapeutic applications. RJR (and subsequently, TARGACEPT) have funded activities involving collaborative research as well as activities involving a sabbatical program. As a result, UKRF and TARGACEPT jointly own
certain technologies (listed in Attachment A, which becomes a part of this agreement), and UKRF has assigned certain technologies to TARGACEPT (listed in Attachment B, which becomes part of this agreement) but which are subject to the terms of that
agreement regarding sharing of royalty income, and 
  
 WHEREAS,
TARGACEPT has entered into an agreement with Rhone-Poulene Rorer, whereby as part of that agreement, certain technologies of TARGACEPT were licensed to Phone-Poulene Rorer; and TARGACEPT is entitled to certain royalty and milestone income, and

  
 WHEREAS, in previous agreements between UKRF and RJR (and
subsequently TARGACEPT), it was agreed that UKRF and RJR would negotiate in good faith towards arriving at terms relating to further use of the technology developed during the 
  

 1 

 collaborative research and sabbatical programs. UKRF and TARGACEPT acknowledge negotiating in good faith towards terms by
which that technology can best be developed for commercial application. 
  
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto agree as follows: 
  
 ARTICLE 1- Definitions 
  
 For the purposes of this agreement, the following words and phrases shall have the following meanings: 
  
 1.1 “TARGACEPT” shall mean Targacept and any subsidiary or
affiliate of Targacept. 
  
 1.2 “Patent Rights” shall
mean the United States and Foreign pending patent applications set forth in Attachments “A” and “B” attached hereto and made a part hereof (hereinafter referred to as the “Patent Rights Patent Application(s)”), and the
United States patents and Foreign patents issuing from said pending United States and Foreign patent applications or later-filed foreign applications based upon any of said United States patents and applications (hereinafter referred to as the
“Patent Rights Patent(s)”) and any continuations, continuations-in-part, divisions reissues or extensions or any of the foregoing. 
  
 1.3 “Licensed Product(s)” shall mean any product made or covered by a pending or issued patent included in the Patent Rights. 
  
 ARTICLE 2- Grant 
  
 2.1 UKRF hereby grants to TARGACEPT the world-wide right and license to the
Patent Rights set forth in Attachment A to the full end of the term of each patent included therein unless sooner terminated as hereinafter provided. This grant is expressly subject to the rights of the U.S. Government, if any. 
  
 2.2 In order to establish a period of exclusivity for TARGACEPT, UKRF hereby
agrees that it shall not grant any other license to make, have made, use, lease and sell the Patent Rights during the period of time commencing with the Effective Date of this Agreement and terminating with the full end of the term of this
Agreement, unless sooner terminated as hereinafter provided. 
  

 2 

 2.3 TARGACEPT shall have the right to sublicense worldwide any of the rights, privileges and license
granted hereunder. 
  
 2.4 Notwithstanding the foregoing, on
behalf of itself and its affiliates, UKRF reserves the right to use the Patent Rights for internal research purposes. 
  
 2.5 TARGACEPT agrees that any sublicenses granted by it shall include a contractual provision granting UKRF the right and ability to proceed directly
against the sublicensee to require such sublicensee to comply with all terms of the sublicense agreement. TARGACEPT further agrees to include the substance of ARTICLES 4, 5, 8, 9, and 10 of this Agreement in all sublicense agreements. 
  
 2.6 TARGACEPT agrees to forward to UKRF a copy of any and all fully executed
sublicense agreements, and further agrees to forward to UKRF annually a copy of such reports received by TARGACEPT from its sublicensees during the preceding twelve (12) month period under the sublicenses as shall be pertinent to a royalty
accounting under said sublicense agreements. 
  
 ARTICLE 3- Due
Diligence 
  
 TARGACEPT shall use its best efforts to bring
the Patent Rights to market through a thorough, vigorous and diligent program for exploitation of the Patent Rights. 
  
 ARTICLE 4- Royalties 
  
 4.1 For the rights, privileges and license granted hereunder, TARGACEPT shall pay to UKRF in the manner hereinafter provided to the end of the term of the Patent Rights or until this Agreement shall be terminated as
hereinafter provided: 
  
 (a) A license issue fee of
[********] Dollars, which said license issue fee shall be deemed earned and due immediately upon the execution of this Agreement. 
  
 (b) For each of the patents described in Attachment A, a royalty in the amount of [********]. 
  
 (c) For each of the patents described in Attachment B, a royalty in the
amount of [********]. Such payments shall only be made if income is based on technology claimed in those patents listed in Attachment B, in countries where those patents are in force. Such payments shall be made for the life of the patents
listed in Attachment B. 
  

 3 

 4.2 As used herein, the phrase “Net Sales Price” shall mean TARGACEPT’s billings for the
Licensed Product(s) produced hereunder less the sum of the following: 
  
 (a) Discounts allowed in amounts customary in the trade; 
  
 (b) Sales, tariff duties and/or use taxes directly imposed and with reference to particular sales; 
  
 (c) Outbound transportation prepaid or allowed; and 
  
 (d) Amounts allowed or credited on returns. 
  
 No deductions shall be made for commissions paid to individuals whether they be with independent sales agencies or regularly employed by TARGACEPT and on
its payroll, or for cost of collections. Licensed Product(s) shall be considered “sold” when billed out or invoiced. 
  
 4.3 No multiple royalties shall be payable because the Licensed Product(s), its manufacture, lease or sale are or shall be covered by more than one patent
application or patent license under this Agreement. 
  
 4.4
Royalty payments shall be paid in United States dollars in Lexington, Kentucky, or at such other place as UKRF may reasonably designate consistent with the laws and regulations controlling in any foreign country. Any withholding taxes which
TARGACEPT or any sublicensee shall be required by law to withhold on remittance of the royalty payments shall be deducted from royalty paid to UKRF. If any currency conversion shall be required in connection with the payment of royalties hereunder,
such conversion shall be made by using the exchange rate prevailing at a first-class foreign exchange bank on the last business day of the calendar quarterly reporting period to which such royalty payments relate. 
  
 ARTICLE 5-Reports and Records 
  
 5.1 TARGACEPT shall keep full, true and accurate books of account containing
all particulars that may be necessary for the purpose of showing the amount payable to UKRF by way of royalty as aforesaid. Said books of account shall be kept at TARGACEPT’s principal place of business or the principal place of business of the

  

 4 

 appropriate division of TARGACEPT to which this Agreement relates. Said books and the supporting data shall be open at
all reasonable times, for five (5) years following the end of the calendar year to which they pertain, to the inspection of the UKRF Internal Audit Division and/or an independent certified public accountant retained by UKRF and/or an accountant
employed by UKRF, for the purpose of verifying TARGACEPT’s royalty statement or compliance in other respects with this Agreement. 
  
 5.2 TARGACEPT, within thirty (30) days after June 30 and December 31, of each year, shall deliver to UKRF true and accurate reports, giving such
particulars of the business conducted by TRAGACEPT during the preceding six-month period under this Agreement as shall be pertinent to a royalty accounting hereunder. These shall include at least the following: 
  
 (a) All Licensed Products manufactured and sold; 
  
 (b) Total billings for Licensed Product sold; 
  
 (c) Deductions applicable as provided in Paragraph 5.2; 
  
 (d) Total royalties due; 
  
 (e) Names and addresses of all sublicensees of TARGACEPT; and 
  
 (f) Annually, the TARGACEPT’s certified financial statements for the
preceding twelve (12) months including, at a minimum, a Balance Sheet and an Operating Statement. 
  
 5.3 With each such report submitted, TARGACEPT shall pay to UKRF the royalties due and payable under this Agreement. If no royalties shall be due,
TARGACEPT shall so report. 
  
 ARTICLE 6-Patent Prosecution

  
 Patent prosecution shall be in accordance with the applicable
collaborative research agreements or sabbatical agreements that gave rise to the patent. 
  
 ARTICLE 7- Termination 
  
 7.1 If TARGACEPT shall become bankrupt or insolvent, or shall file a petition in bankruptcy, or if the business of TARGACEPT shall be placed in the hands of a receiver, assignee or trustee for the benefit of creditors, whether by the
voluntary act of TARGACEPT or otherwise, this Agreement shall automatically terminate. 
  

 5 

 7.2 Should TARGACEPT fail in its payment to UKRF of royalties due in accordance with the terms of this
agreement, UKRF shall have the right to serve notice upon TARGACEPT by certified mail at the address designated herein, of its intention to terminate this Agreement within thirty (30) days after receipt of said notice of termination unless TARGACEPT
shall pay to UKRF, within the thirty (30) day period, all such royalties due and payable. Upon the expiration of the thirty (30) day period, if TARGACEPT shall not have paid all such royalties due and payable, the rights, privileges and license
granted hereunder shall thereupon immediately terminate. 
  
 7.3
Upon any material breach or default of this Agreement by TARGACEPT, other than those occurrences set out in Paragraphs 7.1 and 7.2 hereinabove, which shall always take precedence in that order over any material breach or default referred to in this
Paragraph 7.3, UKRF shall have the right to terminate this Agreement and the rights, privileges and license granted hereunder by ninety (90) days’ notice by certified mail to TARGACEPT. Such termination shall become effective unless TARGACEPT
shall have cured any such breach or default prior to the expiration of the ninety (90) day period from receipt of UKRF’s notice of termination. 
  
 7.4 TARGACEPT shall have the right to terminate this Agreement at any time on six (6) months’ notice by certified mail to UKRF. 
  
 7.5 Upon termination of this Agreement for any reason, nothing herein shall
be construed to release either party from any obligation that matured prior to the effective date of such termination. TARGACEPT and/or any sublicensee thereof may, however, after the effective date of such termination, sell all licensed product in
the process of manufacture at the time of such termination and sell the same, provided that TARGACEPT shall pay to UKRF the royalties theron as required by Article 4 of this Agreement and shall submit the reports required by Article 5 hereof.

  
 ARTICLE 8- Product Liability 
  
 8.1 TARGACEPT shall at all times during the term of this Agreement and
thereafter, indemnify, defend and hold UKRF, the University of Kentucky, their trustees, 
  

 6 

 officers, employees and affiliates, harmless against all claims and expenses, including legal expenses and reasonable
attorneys’ fees, arising out of the death of or injury to any person or persons or out of any damage to property and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from the production,
manufacture, sales, use, consumption or advertisement of any Licensed Product(s) or the Patent Rights or arising from any obligation of TARGACEPT hereunder. 
  
 8.2 If TARGACEPT produces, manufactures or sells any Licensed Product(s), TARGACEPT will maintain product liability insurance, with an endorsement naming
the University of Kentucky Research Foundation, the University of Kentucky, their Board of Trustees, agents officers and employees as additional insureds covering liabilities for the production, manufacture and/or sole of the product. The policy of
insurance shall contain a provision of non-cancellation except upon the provision of sixty (60) days notice to the University. Policy limits shall be not less than $5,000,0000 per person per occurrence. 
  
 8.3 If TARGACEPT, sublicenses any of the rights, privileges and licenses
granted hereunder, TARGACEPT shall require the sublicensee to provide UKRF evidence of such product liability insurance. 
  
 ARTICLE 9- Warranties 
  
 9.1 TARGACEPT AGREES THAT THE RIGHTS GRANTED ARE MADE AVAILABLE WITHOUT WARRANTY OF ANY KIND EXPRESSED OR IMPLIED INCLUDING, BUT NOT LIMITED TO, THE
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND FURTHER INCLUDING NO WARRANTY AS TO CONFORMITY WITH WHATEVER USER MANUALS OR OTHER LITERATURE MAY BE ISSUED FROM TIME TO TIME. 
  
 9.2 TARGACEPT FURTHER AGREES THAT UKRF HAS NOT CONDUCTED NOR HAD CONDUCTED
A PATENTABILITY OR INFRINGEMENT STUDY AND THUS MAKES NO CLAIMS THAT THE LICENSED RIGHTS WILL NOT INFRINGE ANY THIRD PARTIES’ VALID PATENT RIGHTS. 
  

 7 

 ARTICLE 10- Non-Use of Names 
  
 TARGACEPT shall not use the names of the University of Kentucky, University of Kentucky Research Foundation nor of Dr. Peter
Crooks nor any other employee of the University of Kentucky. 
  
 ARTICLE 11- Export Controls 
  
 It is understood
that UKRF us subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended, and the Export Administration Act
of 1979), and that its obligations hereunder are contingent on compliance with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United
States Government and/or written assurances by TARGACEPT that TARGACEPT shall not export data or commodities to certain foreign countries without prior approval of such agency. UKRF neither represents that a license shall not be required nor that,
if required, it shall be issued. 
  
 ARTICLE 12- Payments,
Notices and Other Communications 
  
 Any payment, notice or
other communication pursuant to this Agreement shall be sufficiently made or given on the date of mailing if sent to such party by certified first class mail, postage prepaid, addressed to it at its address below or as it shall designate by written
notice given to the other party: 
  

			
	 In the case of UKRF:
	  	 University of Kentucky Research Foundation

	 	  	 207 Administration Building

	 	  	 Lexington, Kentucky 40506

		
	 With a copy to
	  	 University Legal Counsel

	 	  	 2 Administration Building

	 	  	 Lexington, Kentucky 40506

  

 8 

			
	 In the case of TARGACEPT:
	  	 J.D. deBethizy

	 	  	 Targacept, Inc.

	 	  	 Winston-Salem, NC 27102

  
 ARTICLE 13-
Miscellaneous Provisions 
  
 13.1 This Agreement shall be
construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Kentucky, U.S.A., except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which patent
was granted. 
  
 13.2 The partied hereto acknowledge that this
Agreement sets forth the entire Agreement and understanding of the partied hereto as to the subject matter hereof, and shall not be subject to any change or modification except by the execution of a written instrument subscribed to by the parties
hereto. 
  
 13.3 The provisions of this Agreement are severable,
and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the
remaining provisions hereof. 
  
 13.4 The failure of either party
to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party.

  

 9 

 IN WITNESS WHEREOF, the parties hereto have hereunto set their hands and seals and duly executed this
License Agreement the day and year first set forth below. 
  

									
	 WITNESS:
	 	 	 	 UNIVERSITY OF KENTUCKY

	 	 	 	 	 RESEARCH FOUNDATION

				
	 /s/ Donald G. Keach

	 	 	 	 By:
	 	 /s/ Jeff L. Fink III

	 	 	 	 	 	 	 Title:
	 	 Assistant V.P., RGS

			
	 WITNESS:
	 	 	 	 TARGACEPT, INC.

				
	 /s/ A. J. Borschke

	 	 	 	 By:
	 	 /s/ J. Donald deBethizy

	 	 	 	 	 	 	 Title:
	 	 President

  
 By execution of this
Agreement, the undersigned acknowledge receiving a copy of this Agreement, and of having read and reviewed same prior to its execution by the parties. 
  

			
		
	 By:
	 	 /s/ Peter A. Crooks

	 	 	

	 	 	 Dr. Peter Crooks

  

 10 

 Attachment A 
  
 5,616,707* 
  
 5,726,316 

	*	Also includes Foreign Equivalents 

  

 11 

 Attachment B 
  
 Schedule I 
  
 Applications 
  
 08/885,397* 
 08/885,768* 
 09/098,285* 
 09/177,231* 
  
 Schedule II 
  
 Applications 
  
 09/053,937* 
 09/054,179* 
 09/210,113* 

	*	Also includes Foreign Equivalents 

  

 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]